In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
Conclusions TNBC is a difficult-to-treat oncologic condition, even in an experimental setting. Promising results concerning the addition of targeted therapies (dasatinib) to the conventional cytotoxic ones (docetaxel) have been shown, awaiting further evaluation.PMID:37719631 | PMC:PMC10500968 | DOI:10.7759/cureus.43534
Source: Cancer Control - Category: Cancer & Oncology Authors: Ioannis D Passos Dimochristos Papadimitriou Areti Katsouda Georgios E Papavasileiou Apostolos Galatas Panagiotis Tzitzis Alexandra Mpakosi Maria Mironidou-Tzouveleki Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Statistics | Study | Taxotere